{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-035834","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.076967+00:00","generated_at":"2026-06-17T18:00:28.994236+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update","bullets":["Completed enrollment in Phase 2 SEQUEL trial of CT1812 for mild-to-moderate Alzheimer's disease; topline results expected later 2023.","Received FDA clearance for Phase 2 START study of CT1812 in early Alzheimer's disease and IND clearance for Phase 2 trial in geographic atrophy.","Secured up to $35M equity commitment from Lincoln Park Capital and completed $6M follow-on public offering.","Cash and cash equivalents $41.6M as of Dec 31, 2022, expected to fund operations into second half of 2024.","Net loss for 2022 was $21.4M ($0.91 per share) compared to $11.7M ($3.13 per share) in 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-035834","json":"https://secwatch.observer/filing/0001104659-23-035834.json","markdown":"https://secwatch.observer/filing/0001104659-23-035834.md","text":"https://secwatch.observer/filing/0001104659-23-035834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923035834/0001104659-23-035834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923035834/tm2310284d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:00:28.994236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"baf95e1d2ff8f71a0bf22b2084d3b15f0b00f4a2","claim":"COGNITION THERAPEUTICS INC reported the year ended December 31, 2022 results: net income $21.4 million, EPS $0.91 per basic and diluted share.","evidence_excerpt":"For the year ended December 31, 2022, Cognition Therapeutics reported a net loss of $21.4 million, or $0.91 per basic and diluted share, compared to a net loss of $11.7 million, or $3.13 per basic and diluted share for 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923035834/0001104659-23-035834-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$21.4 million"},{"label":"EPS","value":"$0.91 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}